Arbutus Biopharma Corp - ESG Rating & Company Profile powered by AI
If you are employed by Arbutus Biopharma Corp and you wish to use your Sustainability rating, please get in touch. The page is a free Environmental, Social and Governance assessment covering Arbutus Biopharma Corp. The ESG assessment for Arbutus Biopharma Corp indicates the company's reporting of the UN Sustainable Development Goals.
Arbutus Biopharma Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.4; made up of an environmental score of 2.0, social score of 4.8 and governance score of 6.4.
4.4
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 868 | Trevena Inc | 4.5 | High |
| 868 | Urogen Pharma Ltd | 4.5 | High |
| 910 | Arbutus Biopharma Corp | 4.4 | High |
| 910 | CanBas Co Ltd | 4.4 | High |
| 910 | CNS Pharmaceuticals Inc | 4.4 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Arbutus Biopharma Corp have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose current and historical energy intensity?
Sign up for free to unlockDoes Arbutus Biopharma Corp report the average age of the workforce?
Sign up for free to unlockDoes Arbutus Biopharma Corp reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose its ethnicity pay gap?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose cybersecurity risks?
Sign up for free to unlockDoes Arbutus Biopharma Corp offer flexible work?
Sign up for free to unlockDoes Arbutus Biopharma Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Arbutus Biopharma Corp conduct supply chain audits?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Arbutus Biopharma Corp conduct 360 degree staff reviews?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose the individual responsible for D&I?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose water use targets?
Sign up for free to unlockDoes Arbutus Biopharma Corp have careers partnerships with academic institutions?
Sign up for free to unlockDid Arbutus Biopharma Corp have a product recall in the last two years?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose incidents of discrimination?
Sign up for free to unlockDoes Arbutus Biopharma Corp allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Arbutus Biopharma Corp issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose parental leave metrics?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose the pay ratio of women to men?
Sign up for free to unlockDoes Arbutus Biopharma Corp support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Arbutus Biopharma Corp reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Arbutus Biopharma Corp involved in embryonic stem cell research?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose its waste policy?
Sign up for free to unlockDoes Arbutus Biopharma Corp report according to TCFD requirements?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose energy use targets?
Sign up for free to unlockDoes Arbutus Biopharma Corp disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Arbutus Biopharma Corp have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Arbutus Biopharma Corp
These potential risks are based on the size, segment and geographies of the company.
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.